This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

11 Biotech Stocks Loved or Hated by Hedge Funds

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oncothyreon (ONTY)

Another cancer immunotherapy, or "cancer vaccine" stock hoping to replicate the success of Dendreon while sidestepping Provenge's problems. Oncothyreon and its partner Merck KGaA are gearing up to perform an interim analysis on a phase III study of their Stimuvax immunotherapy in non-small cell lung cancer patients. Trading volume and volatility in Oncothyreon have increased dramatically in recent months as investors focus hard on this interim analysis, which is expected in the first quarter of next year.

Year to date performance: + 107%

Performance since June 30: -26%

Three hedge funds -- Biotechnology Value Fund (BVF), Orbimed Advisors and Black Horse Capital -- added significant new Oncothyreon positions in the second quarter. Each firm owned well over 1 million shares of the company as of June 30. Antipodean Advisors bought 1.6 million shares during the quarter to bring its total holding to 2.3 million shares.

Selling hedge funds included RA Capital, which liquidated its 236,000-share position in Oncothyreon during the second quarter. Straus Capital Management and Highland Capital Management also were sellers.

2 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
IDIX $24.50 0.20%
AMRN $1.97 0.00%
DSCI $7.84 0.00%
KERX $10.48 0.00%
ONTY $1.47 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs